Concert Pharmaceuticals to Report Third Quarter 2022 Results on November 7, 2022
LEXINGTON, Mass.--(BUSINESS WIRE)--Oct 31, 2022--
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the third quarter of 2022, on Monday, November 7, 2022, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss its third quarter 2022 financial results and provide a business update.
To join the live call to ask questions, please register here. A dial in and unique PIN will be provided to join the call.
An audio-only webcast of the call may be accessed in the Investors section of the Company’s website at www.concertpharma.com. A replay of the webcast will be available on Concert’s website for three months.
About Concert
Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing deuruxolitinib (CTP-543), a novel, deuterated, oral JAK1/2 inhibitor. Concert has successfully completed two Phase 3 trials with deuruxolitinib in adults with alopecia areata, a serious autoimmune dermatological disease. The Company is also evaluating the use of deuruxolitinib in other indications and assessing a number of earlier-stage pipeline candidates. For more information, please visit www.concertpharma.com or follow us on Twitter, Instagram or LinkedIn.
View source version on businesswire.com:https://www.businesswire.com/news/home/20221031005054/en/
CONTACT: Justine Koenigsberg
(781) 674-5284
ir@concertpharma.com
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH CLINICAL TRIALS
SOURCE: Concert Pharmaceuticals, Inc.
Copyright Business Wire 2022.
PUB: 10/31/2022 07:00 AM/DISC: 10/31/2022 07:01 AM
http://www.businesswire.com/news/home/20221031005054/en
